Everything below concerns actin-binding motif. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-08-31. Numbers and descriptions here follow the published literature rather than marketing material.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Lyophilized peptide arrives as a dry cake that should stay sealed until use. Reconstitution is generally performed with sterile water or a buffered solution, and the resulting liquid should be handled gently to limit mechanical stress. Repeated freeze-thaw cycles are widely described as harmful to short peptides, so dividing a reconstituted batch into single-use portions is a common practice. Laboratories also record the solvent, concentration, and date of preparation on the vial label to keep later measurements traceable.
Dry powder is commonly held at minus twenty degrees Celsius, with some suppliers recommending lower temperatures for long-term archival storage. Once dissolved, solutions are typically kept cold and protected from light, since aqueous peptide solutions can lose integrity through hydrolysis or oxidation over time. Stability data specific to this fragment are limited in the public literature, and much of the guidance comes from general peptide handling practice rather than from controlled degradation studies. Users therefore treat stated shelf lives as approximate rather than fixed.
Identity and purity are normally assessed with reversed-phase high-performance liquid chromatography, paired with mass spectrometry to confirm molecular mass. A certificate of analysis reports a purity percentage, usually derived from chromatographic peak area, but that figure does not by itself prove a correct sequence or the absence of counterions. Independent verification may include amino acid analysis or peptide mapping. Batch-to-batch variation is a documented concern in the research chemical market, and the gap between a quoted purity value and actual peptide content can be substantial when the material is a salt or retains residual water.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Typical form for short synthetic peptides |
| Solubility class | Freely soluble in water and aqueous buffer | Dissolution aided by gentle mixing, not vigorous shaking |
| Typical storage temperature | −20 °C, desiccated | −80 °C used for long-term holding |
| Common analytical method | Reverse-phase HPLC with UV detection near 214 nm | Identity confirmed separately by mass spectrometry |
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming varies between suppliers and publications |
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
== Fusion in eukaryotes == Eukaryotic genomes contain several gene families, of host and viral origin, which encode products involved in driving membrane fusion. While adult somatic cells do not typically undergo membrane fusion under normal conditions, gametes and embryonic cells follow developmental pathways to non-spontaneously drive membrane fusion, such as in placental formation, syncytiotrophoblast formation, and neurodevelopment. Fusion pathways are also involved in the development of musculoskeletal and nervous system tissues. Vesicle fusion events involved in neurotransmitter trafficking also relies on the catalytic activity of fusion proteins.
== Regulation == MTHFR activity may be inhibited by binding of dihydrofolate (DHF) and S-adenosyl methionine (SAM, or AdoMet). MTHFR can also be phosphorylated – this decreases its activity by ~20% and allows it to be more easily inhibited by SAM.
For instance, 4-methylfentanyl, 4'-methylfentanyl and 4"-methylfentanyl are all known compounds, as are 3-methylthio-fentanyl and 3-methyl-thiofentanyl, all of which have varying potencies and pharmacokinetics. Confusion between different positional isomers is especially significant in the case of fentanyls because of the huge variation in potency between different members of the class. The weakest compounds such as benzylfentanyl are around the same potency as codeine (i.e. approximately 1/10th the potency of morphine), while the strongest compounds such as carfentanil and ohmefentanil can be over 10,000x more potent than morphine, meaning there is a 100,000-fold variation in potency between the strongest and weakest fentanyl derivatives. This means that two positional isomers with the same molecular weight, which may be difficult to tell apart without detailed chemical analysis, may be hundreds or even thousands of times different in pharmacological potency. Also the wide variety of substitutions that have been used on the basic fentanyl structure, each of which can either reduce or increase the potency, can be unpredictable when used in combination, so it may be impossible to estimate the likely potency of newly discovered analogues until pharmacological testing has been carried out.
Sources: en.wikipedia.org
=== Methods of assessment === An increase in prothrombin time, a coagulation assay, has been used as an indicator of vitamin K status, but it lacks sufficient sensitivity and specificity for this application. Serum phylloquinone is the most commonly used marker of vitamin K status. Concentrations <0.15 μg/L are indicative of deficiency. Disadvantages include exclusion of the other vitamin K vitamers and interference from recent dietary intake. Vitamin K is required for the gamma-carboxylation of specific glutamic acid residues within the Gla domain of the 17 vitamin K–dependent proteins. Thus, a rise in uncarboxylated versions of these proteins is an indirect but sensitive and specific marker for vitamin K deficiency.
Second, Downstream-peptides are consistently positioned in a place that is consistent with a cis-regulatory role in regulating the downstream ORFs, although the biological role of the ORFs is unknown. Third, the pseudoknot structure has a moderate complexity that is typical of riboswitches. Finally, the observation of regulation of a downstream ORF by nitrogen availability also suggests a cis-regulatory role of the element. This hypothesis is supported by biochemical and genetic data. First, both Downstream-peptide RNAs and glnA RNAs selectively bind glutamine. Second, reporter gene analysis of the Downstream-peptide motif revealed that this RNA promotes reporter gene expression upon binding of glutamine and can therefore be considered an activating riboswitch. Possible candidates to be regulated by the Downstream-peptide motif are genes that frequently carry the Downstream-peptide motif in their 5′UTR and encode small, unknown proteins that contain DUF4278 and are putative regulators of glutamine synthetase. This hypothesis is supported by the finding that expression of the DUF4278-containing glutamine synthetase inhibitory factor IF17 encoding gene gifB was shown to be regulated by the structurally related glnA RNA motif. Downstream-peptide RNAs overlap a predicted non-coding RNA called yfr6 that is over 200 nucleotides in length, but it was proposed that only the upstream region (corresponding to the Downstream-peptide motif) functions as an RNA structure. A distinct predicted non-coding RNA called yfr14 overlaps both yfr6 and Downstream-peptide RNAs.
In 1600 BCE, the Edwin Smith Papyrus, an Ancient Egyptian medical text, described the heart and its vessels, as well as the brain and its meninges and cerebrospinal fluid, and the liver, spleen, kidneys, uterus and bladder. It showed the blood vessels diverging from the heart. The Ebers Papyrus (c. 1550 BCE) features a "treatise on the heart", with vessels carrying all the body's fluids to or from every member of the body. The Hellenistic Egyptian city of Alexandria was the stepping-stone for Greek anatomy and physiology. Alexandria not only housed the biggest library for medical records and books of the liberal arts in the world during the time of the Greeks but was also home to many medical practitioners and philosophers. Great patronage of the arts and sciences from the Ptolemaic dynasty of Egypt helped raise Alexandria up, further rivalling other Greek states' cultural and scientific achievements.
Sources: en.wikipedia.org
High throughput analysis is a significant advantage in the use of DMF systems, but means that they are particularly susceptible to cross contamination between experiments. As a result, the coupling of DMF with mass spectrometry often requires the integration of a variety of methods to prevent cross contamination such as multiple washing steps, biologically compatible surfactants, and or super hydrophobic surfaces to prevent droplet adsorption. In one example, a reduction in cross contaminant signal during the characterization of an amino acid required 4-5 wash steps between each sample droplet for the contamination intensity to fall below the limit of detection.
On 14 March, an international group of researchers presented a preliminary analysis at a meeting of the World Health Organization's Scientific Advisory Group for Origins of Novel Pathogens, at which Chinese COVID-19 researchers were also present. On the sixteenth, George Gao, the former head of the CCDC and lead author on the February 2022 preprint, told Science that there was "nothing new" in the raw data, and refused to answer questions about why his research team had removed it from the database. On 17 March, the WHO director-general said that the data should have been shared three years earlier, and called on China to be more transparent in its data-sharing. There exists further data from further samples which has not yet been made public. Maria Van Kerkhove, the WHO's COVID-19 technical lead, called for it to be made public immediately (see Huanan live-animal market#Swabs).
At a 2016 meeting with Pope Francis, DiCaprio donated to charity and discussed environmental issues with him. A few days later, possibly influenced by this meeting, the Pope said he would act in a charity film. DiCaprio traveled to Indonesia in early 2016 where he criticized the government's palm oil industry's slash-and-burn forest clearing methods. In July 2016, his foundation donated $15.6 million to help protect wildlife and the rights of Native Americans, along with mitigating climate change. That October, DiCaprio joined Mark Ruffalo in support of the Standing Rock tribe's opposition to the Dakota Access Pipeline. In April 2017, DiCaprio protested against President Donald Trump's inaction on climate change by attending the People's Climate March. In July, a charity auction and celebrity concert arranged by DiCaprio's foundation had raised over $30 million in one night. The DiCaprio foundation donated $100 million in December 2018 to fight climate change. In May 2021, DiCaprio pledged $43 million to enact conservation operations across the Galápagos Islands.
Sources: en.wikipedia.org
TB-500 is a trade-style label for a synthetic peptide connected to thymosin beta-4. It is sold mainly through research-chemical channels and is not a single chemically defined product across suppliers.
Not necessarily. Some vendors use the name for the full 43-residue protein, while others apply it to a short actin-binding fragment or to a related tetrapeptide. The sequence should be confirmed from documentation rather than assumed from the label.
No thymosin beta-4 fragment holds marketing approval as a medicine in major jurisdictions. Material offered for sale is typically labelled for laboratory research only.
Dry lyophilized powder is usually kept frozen, desiccated, and out of direct light. Sealed vials are not opened until needed, because moisture uptake can degrade short peptides. Longer archival storage is often done at lower temperatures than routine working stock.